BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bayda N, Tilloy V, Chaunavel A, Bahri R, Halabi MA, Feuillard J, Jaccard A, Ranger-Rogez S. Comprehensive Epstein-Barr Virus Transcriptome by RNA-Sequencing in Angioimmunoblastic T Cell Lymphoma (AITL) and Other Lymphomas. Cancers (Basel) 2021;13:610. [PMID: 33557089 DOI: 10.3390/cancers13040610] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Yap LF, Wong AKC, Paterson IC, Young LS. Functional Implications of Epstein-Barr Virus Lytic Genes in Carcinogenesis. Cancers 2022;14:5780. [DOI: 10.3390/cancers14235780] [Reference Citation Analysis]
2 Chakravorty S, Afzali B, Kazemian M. EBV-associated diseases: Current therapeutics and emerging technologies. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1059133] [Reference Citation Analysis]
3 Donzel M, Bonjour M, Combes JD, Broussais F, Sesques P, Traverse-Glehen A, de Martel C. Lymphomas associated with Epstein-Barr virus infection in 2020: Results from a large, unselected case series in France. EClinicalMedicine 2022;54:101674. [PMID: 36204003 DOI: 10.1016/j.eclinm.2022.101674] [Reference Citation Analysis]
4 Donzel M, Perier-muzet M, Balme B, Lemonnier F, Ingen-housz-oro S, Dalle S, Ortonne N. Manifestations cutanées des lymphomes T angio-immunoblastiques. Annales de Dermatologie et de Vénéréologie - FMC 2022. [DOI: 10.1016/j.fander.2022.07.003] [Reference Citation Analysis]
5 Ibrahim D, Prévaud L, Faumont N, Troutaud D, Feuillard J, Diab-Assaf M, Oulmouden A. Alternative c-MYC mRNA Transcripts as an Additional Tool for c-Myc2 and c-MycS Production in BL60 Tumors. Biomolecules 2022;12:836. [PMID: 35740961 DOI: 10.3390/biom12060836] [Reference Citation Analysis]
6 Bahri R, Boyer F, Halabi MA, Chaunavel A, Feuillard J, Jaccard A, Ranger-Rogez S. Epstein-Barr Virus (EBV) Is Mostly Latent and Clonal in Angioimmunoblastic T Cell Lymphoma (AITL). Cancers (Basel) 2022;14:2899. [PMID: 35740565 DOI: 10.3390/cancers14122899] [Reference Citation Analysis]
7 Schlecht-Louf G, Deback C, Bachelerie F. The Chemokine System in Oncogenic Pathways Driven by Viruses: Perspectives for Cancer Immunotherapy. Cancers (Basel) 2022;14:848. [PMID: 35159113 DOI: 10.3390/cancers14030848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Knerr JM, Kledal TN, Rosenkilde MM. Molecular Properties and Therapeutic Targeting of the EBV-Encoded Receptor BILF1. Cancers (Basel) 2021;13:4079. [PMID: 34439235 DOI: 10.3390/cancers13164079] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Ma H, O'Connor OA, Marchi E. Management of Angioimmunoblastic T-Cell Lymphoma (AITL) and other T Follicular Helper Cell lymphomas (TFH PTCL). Semin Hematol 2021;58:95-102. [PMID: 33906727 DOI: 10.1053/j.seminhematol.2021.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]